Subscribe To
The ratings game: ‘we see few catalysts.' netflix hit with wall street downgrades after disappointing subscriber forecast
Watch what's next?...
January 21, 2022, 7:19 am
Nio has big plans for 2022, but the nio stock recovery might take longer
Nio stock has plenty of catalysts for 2022 including the launch of multiple new models, but it will fac...
January 20, 2022, 4:15 pm
Nio has big plans for 2022, but the nio stock recovery might take longer
Nio stock has plenty of catalysts for 2022 including the launch of multiple new models, but it will fac...
January 20, 2022, 4:15 pm
Nio has big plans for 2022, but the nio stock recovery might take longer
Nio stock has plenty of catalysts for 2022 including the launch of multiple new models, but it will fac...
January 20, 2022, 4:15 pm
Atex resources, a porphyry copper-gold opportunity in chile: this stock has significant upside potential, near-term catalysts
ATEX Resources is exploring the advanced-stage Valeriano project in Chile, with inferred resources from historical drilling at 0.62 Moz of oxide gold ...
January 20, 2022, 3:23 pm
Atex resources, a porphyry copper-gold opportunity in chile: this stock has significant upside potential, near-term catalysts
ATEX Resources is exploring the advanced-stage Valeriano project in Chile, with inferred resources from historical drilling at 0.62 Moz of oxide gold ...
January 20, 2022, 3:23 pm
Atex resources, a porphyry copper-gold opportunity in chile: this stock has significant upside potential, near-term catalysts
ATEX Resources is exploring the advanced-stage Valeriano project in Chile, with inferred resources from historical drilling at 0.62 Moz of oxide gold ...
January 20, 2022, 3:23 pm
Cytokinetics: biotech that should be on your radar with several catalysts in 2022
Cytokinetics establishes partnership deal with Royalty Pharma for omecamtiv mecarbil and aficamten. Up to $450 million in total is expected for this p...
January 7, 2022, 7:51 pm
Cytokinetics: biotech that should be on your radar with several catalysts in 2022
Cytokinetics establishes partnership deal with Royalty Pharma for omecamtiv mecarbil and aficamten. Up to $450 million in total is expected for this p...
January 7, 2022, 7:51 pm
Cytokinetics: biotech that should be on your radar with several catalysts in 2022
Cytokinetics establishes partnership deal with Royalty Pharma for omecamtiv mecarbil and aficamten. Up to $450 million in total is expected for this p...
January 7, 2022, 7:51 pm
Myovant: catalysts powering more upside
Due to the combination of a market downturn and other issues, Myovant shares depreciated substantially. Nevertheless, there are powerful fundamental a...
January 2, 2022, 1:45 pm
Myovant: catalysts powering more upside
Due to the combination of a market downturn and other issues, Myovant shares depreciated substantially. Nevertheless, there are powerful fundamental a...
January 2, 2022, 1:45 pm
Myovant: catalysts powering more upside
Due to the combination of a market downturn and other issues, Myovant shares depreciated substantially. Nevertheless, there are powerful fundamental a...
January 2, 2022, 1:45 pm
Nvax stock dips ahead of potential novavax catalyst. what to know.
Here's what investors may want to know about Novavax and NVAX stock, as shares continue to decline despite key...
December 27, 2021, 12:59 pm
Nvax stock dips ahead of potential novavax catalyst. what to know.
Here's what investors may want to know about Novavax and NVAX stock, as shares continue to decline despite key...
December 27, 2021, 12:59 pm
Nvax stock dips ahead of potential novavax catalyst. what to know.
Here's what investors may want to know about Novavax and NVAX stock, as shares continue to decline despite key...
December 27, 2021, 12:59 pm
Cara therapeutics: de-risked and extremely attractive
Cara received approval for IV KORSUVA in August. Since then, the stock has gone in circles without any catalys...
December 25, 2021, 5:58 am
Cara therapeutics: de-risked and extremely attractive
Cara received approval for IV KORSUVA in August. Since then, the stock has gone in circles without any catalys...
December 25, 2021, 5:58 am
Cara therapeutics: de-risked and extremely attractive
Cara received approval for IV KORSUVA in August. Since then, the stock has gone in circles without any catalys...
December 25, 2021, 5:58 am
Why is transportation m&a so hot?
M&A in the transportation and logistics industry was up in a big way in 2021. Many of the catalysts in ...
December 19, 2021, 10:00 am